Abiraterone Other names: Abiraterone Acetate

Chemical formula: C₂₄H₃₁NO  Molecular mass: 349.509 g/mol  PubChem compound: 132971

Active ingredient description

Abiraterone acetate is converted in vivo to abiraterone, an androgen biosynthesis inhibitor. Specifically, abiraterone selectively inhibits the enzyme 17α-hydroxylase/C17,20-lyase (CYP17). This enzyme is expressed in and is required for androgen biosynthesis in testicular, adrenal and prostatic tumour tissues. CYP17 inhibition also results in increased mineralocorticoid production by the adrenals.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code Group title Classification
L02BX03 Abiraterone L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02B Hormone antagonists and related agents → L02BX Other hormone antagonists and related agents
Discover more medicines within L02BX03

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title Information Source Document Type  
ZYTIGA Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
ZYTIGA Tablet European Medicines Agency (EU) MPI, EU: SmPC

Structural formula

Graphic representation of the active ingredient's molecular structure

External identifiers

CAS Substance: 154229-19-3
DrugBank Drug: DB05812
KEGG Drug: D09701
PubChem Compound: 132971
RxNorm Ingredient: 1100072
SNOMED-CT Concept: 699678007
Abiraterone (substance)
UNII Identifier: G819A456D0
ABIRATERONE

Medicines

Abiraterone is an active ingredient of these brands:

United States (US)

  • YONSA as ABIRATERONE ACETATE
  • ZYTIGA as ABIRATERONE ACETATE

Australia (AU)

  • ZYTIGA as ABIRATERONE ACETATE

Austria (AT)

  • ZYTIGA as ABIRATERONE ACETATE

  • (combination) AKEEGA as ABIRATERONE ACETATE

Brazil (BR)

Canada (CA)

  • ZYTIGA as ABIRATERONE ACETATE

Croatia (HR)

  • (combination) AKEEGA as ABIRATERONE ACETATE

Cyprus (CY)

  • ZYTIGA as ABIRATERONE ACETATE

Ecuador (EC)

Estonia (EE)

  • ZYTIGA as ABIRATERONE ACETATE

France (FR)

  • ZYTIGA as ABIRATERONE ACETATE

  • (combination) AKEEGA as ABIRATERONE ACETATE

Hong Kong (HK)

Ireland (IE)

  • ZYTIGA as ABIRATERONE ACETATE

Israel (IL)

  • ZYTIGA as ABIRATERONE ACETATE

Japan (JP)

  • ZYTIGA as ABIRATERONE ACETATE

Lithuania (LT)

  • TATICA as ABIRATERONE ACETATE
  • ZYTIGA as ABIRATERONE ACETATE

  • (combination) AKEEGA as ABIRATERONE ACETATE

Mexico (MX)

  • ZYTIGA as ABIRATERONE ACETATE

Netherlands (NL)

  • ZYTIGA as ABIRATERONE ACETATE

New Zealand (NZ)

  • YONSA as ABIRATERONE ACETATE
  • ZYTIGA as ABIRATERONE ACETATE

Nigeria (NG)

  • ZYTIGA as ABIRATERONE ACETATE

Poland (PL)

Romania (RO)

Singapore (SG)

South Africa (ZA)

Spain (ES)

  • ZYTIGA as ABIRATERONE ACETATE

Tunisia (TN)

  • ZYTIGA as ABIRATERONE ACETATE

Turkey (TR)

United Kingdom (UK)

  • ZYTIGA as ABIRATERONE ACETATE

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.